- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01251354
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Georgia
-
Augusta, Georgia, 미국, 30912
- Dept of Obstetrics and Gynecology, Medical College of Georgia
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- Division of Gynecologic Oncology, University of Minnesota Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104-4283
- Jordan Center for Gynecologic Cancer at Penn, University of Pennsylvania
-
Upland, Pennsylvania, 미국, 19103
- Crozer Chester Medical Center
-
-
-
-
Ontario
-
London, Ontario, 캐나다, N6A 4L6
- London Health Sciences Centre, University of Western Ontario
-
Ottawa, Ontario, 캐나다, K1H 8L6
- Department of Oncology, Ottawa Cancer Center
-
Toronto, Ontario, 캐나다, M5G 2M9
- Dept of Obstetrics and Gynecology, Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2L 4M1
- CHUM-Hospital Notre-Dame Service de Gynecologic Oncologique
-
Montreal, Quebec, 캐나다, H2W 1S6
- Department of Oncology, McGill University
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Provision of written informed consent prior to any study related procedures.
- postmenopausal or ovariectomised female patient over 18 years of age.
- histologically confirmed diagnosis of ER positive endometrial carcinoma in the primary tumour or metastatic disease
- patient has received one line of chemotherapy prior to enrolment in the adjuvant or in the metastatic setting (including chemoradiotherapy) and progressed after this line of chemotherapy
- patient has at least one measurable disease site (RECIST criteria version 1.1)
Exclusion Criteria:
- patient has received hormone therapy for endometrial cancer in the adjuvant or metastatic setting
- patient has received more than one line of chemotherapy in the adjuvant or metastatic setting
- patient was treated with any other investigational agent within the 3 weeks before study entry.
- patient has ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade (NCI CTCAE) or QTcF interval >460 msec.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: BN83495
|
1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Determination of Clinical Benefit (CB), Defined as Sum of Patients Who Present Complete Response (CR), Partial Response (PR) or Stable Disease (SD) ≥12 Weeks (CB=CR+PR+SD≥12 Weeks) Using Response Evaluation Criteria in Solid Tumors (RECIST Version1.1)
기간: 12 weeks
|
CR defined as: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR defined as: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD defined as: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study. PD defined as: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Adverse Events
기간: Up to 28 days after last dose
|
Up to 28 days after last dose
|
|
Determination of Time to Progression (TTP) in This Patient Population
기간: After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Time to Progression (TTP): Time from first study treatment to first documentation of objective tumour progression.
|
After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Determination of Progression Free Survival (PFS) in This Patient Population
기간: After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Progression Free Survival (PFS): Time from first study treatment until objective tumour progression or death from any cause.
|
After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Determination of Overall Response Rate (ORR) in This Patient Population
기간: After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Overall Response Rate (ORR): Defined as the sum of CR and PR.
|
After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Determination of Duration of Response in This Patient Population
기간: After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Duration of Response (DR): Time from the first documentation of objective tumour response (defined as CR or PR) to the first documentation of objective tumour progression or death on study due to any cause.
|
After the last enrolled patient has been followed for at least 6 months or has progressed or died
|
Determination of Overall Survival in This Patient Population
기간: 2 years after the last patient enrolled
|
Overall Survival (OS): Defined as the time from first study treatment to death due to any cause.
|
2 years after the last patient enrolled
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
자궁내막암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
BN83495에 대한 임상 시험
-
Imperial College LondonUniversity of Southern California; Guy's and St Thomas' NHS Foundation Trust; Ipsen; National... 그리고 다른 협력자들종료됨
-
Imperial College LondonCancer Research UK완전한
-
Ipsen완전한자궁내막암체코, 프랑스, 영국, 벨기에, 라트비아, 헝가리, 리투아니아, 몰도바 공화국, 폴란드, 러시아 연방, 스페인, 우크라이나